H.C. Wainwright assumed coverage of Can-Fite BioPharma (CANF) with a Buy rating and $2.50 price target The firm says the company has two late-stage oral selective A3 adenosine receptor agonists, that are being developed as therapies for psoriasis and liver cancer, respectively. It believes A3AR agonists are novel and can selectively target pathogenic cells.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CANF:
- Can-Fite BioPharma Reschedules Shareholder Meeting Due to Lack of Quorum
- Can-Fite BioPharma’s Phase 3 Psoriasis Study: A Potential Game Changer?
- Can-Fite BioPharma’s Promising Phase 3 Trial for Liver Cancer Treatment
- Can-Fite BioPharma’s Promising Phase 2 Study on Namodenoson for Pancreatic Cancer
- Can-Fite BioPharma Announces Special Shareholder Meeting for Capital Restructuring